Teva to sell assets in global women’s health business for $1.38bn
Teva Pharmaceutical Industries has entered two agreements to divest the remaining stake in its specialist global women’s health business for…
All articles by Lopamudra Roy
Lopamudra Roy
-
-
Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases
Immunocore has secured up to $40m in investment from Bill & Melinda Gates Foundation to boost the development of soluble…
-
NUS study shows Artemisinin-ALA co-treatment could destroy cancer cells
A new study conducted by researchers from the National University of Singapore (NUS) has revealed that the co-treatment using artemisinin…
-
GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing…
-
Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs
Bristol-Myers Squibb has entered a global collaboration and licence agreement to use Halozyme Therapeutics’ Enhanze drug-delivery technology for the development…
-
Evotec and MaRS Innovation launch new drug-discovery partnership
German company Evotec and Canada-based MaRS Innovation (MI) have launched a joint partnership ‘LAB150’ in Toronto, Ontario, Canada.The five-year partnership…
-
Fujifilm opens new cell culture process development laboratories in UK
Fujifilm Diosynth Biotechnologies has opened new and advanced 10,000ft² cell culture process development laboratories in Wilton Centre, Teesside, UK.The company…
-
Monopar receives licence to develop Onxeo’s Validive oral mucositis treatment
Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat…
-
US FDA advisory committee votes for GSK’s Shingrix to prevent shingles
The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted unanimously for GlaxoSmithKline’s…
-
Janssen to stop further development of JNJ-4178 hepatitis C treatment
Janssen Sciences Ireland has taken a strategic decision to discontinue further development of its investigational regimen JNJ-4178 for the treatment…